Related Experiment Video

Updated: May 31, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type

Erhan Aptullahoglu1,2, Mohammed Howladar1, Jonathan P Wallis3

  • 1Biosciences Institute & Newcastle University Cancer Centre, Medical Faculty, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Cancers
|January 25, 2025
PubMed

Insights

HDM201 shows promise for treating chronic lymphocytic leukemia (CLL) with wild-type TP53. However, TP53 mutations confer resistance, indicating TP53 status is crucial for predicting treatment response in CLL patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) treatment is evolving towards targeted therapies, yet challenges like drug resistance and incomplete responses remain.
  • The MDM2-p53 interaction is a key regulator of p53 tumor suppressor function, making it a target for novel cancer therapies.
  • Understanding the role of TP53 genetic status is critical for optimizing targeted therapy selection in CLL.

Purpose of the Study:

  • To evaluate the efficacy of HDM201, a second-generation MDM2-p53 binding antagonist, as a novel therapeutic strategy for CLL.
  • To investigate the impact of different TP53 genetic contexts (wild-type, heterozygous knockout, homozygous knockout, and mutations) on HDM201 sensitivity.
  • To assess the potential of HDM201 in primary CLL samples with varying TP53 backgrounds.

Main Methods:

  • Utilized a panel of B cell leukemia-derived cell lines, including TP53-knockout (KO) Nalm-6 derivatives.
  • Assessed HDM201's effects on cell viability, p53 stabilization, and apoptosis induction.
  • Tested HDM201 activity on primary CLL patient samples with wild-type and mutant TP53.

Main Results:

  • HDM201 demonstrated sensitivity in TP53 wild-type and heterozygous TP53-KO cells, stabilizing p53 and inducing apoptosis.
  • Significant resistance to HDM201 was observed in homozygous TP53-KO cells and cells with TP53 mutations.
  • Primary CLL samples with TP53 mutations also exhibited resistance to HDM201 treatment.

Conclusions:

  • HDM201 shows potential as an additional targeted therapy for CLL patients with wild-type TP53.
  • TP53 genetic status is a key predictive biomarker for HDM201 treatment efficacy in CLL.
  • Further research is warranted to explore HDM201 in combination therapies and identify additional response biomarkers for improved CLL outcomes.
Keywords:
MDM2-p53 antagonistschronic lymphocytic leukemia (CLL)p53p53-dependent apoptosissiremadlin (HDM201)

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K